AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-economic impact and the burden for the family. Pidotimod is a synthetic immunostimulant. The aim of this study was to evaluate the effects of pidotimod on RRI prevention in children. METHODS: Globally, 100 children (49 males, mean age 4.7 ± 1.2 years) with RRI were enrolled in the study. At baseline, children were randomly assigned to the treatment with pidotimod 400 mg/die or not for two months. Children were visited at baseline, after 30 (T1) and 60 (T2) days, and at follow-up (120 days; T3). Number of children with upper and lower airways symptoms, medications use, school attendance, and paediatric visits for RRI were evaluated. RESULTS: Pidotimod treatment was able of significantly reducing the number of children with upper and lower airways symptoms, and medications use, increasing school attendance, and reducing pediatric visits for RRI. CONCLUSION: This study provided the evidence that pidotimod may be able of preventing RRI in children.
RCT Entities:
AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-economic impact and the burden for the family. Pidotimod is a synthetic immunostimulant. The aim of this study was to evaluate the effects of pidotimod on RRI prevention in children. METHODS: Globally, 100 children (49 males, mean age 4.7 ± 1.2 years) with RRI were enrolled in the study. At baseline, children were randomly assigned to the treatment with pidotimod 400 mg/die or not for two months. Children were visited at baseline, after 30 (T1) and 60 (T2) days, and at follow-up (120 days; T3). Number of children with upper and lower airways symptoms, medications use, school attendance, and paediatric visits for RRI were evaluated. RESULTS:Pidotimod treatment was able of significantly reducing the number of children with upper and lower airways symptoms, and medications use, increasing school attendance, and reducing pediatric visits for RRI. CONCLUSION: This study provided the evidence that pidotimod may be able of preventing RRI in children.
Authors: Susanna Esposito; Manuel E Soto-Martinez; Wojciech Feleszko; Marcus H Jones; Kun-Ling Shen; Urs B Schaad Journal: Curr Opin Allergy Clin Immunol Date: 2018-06
Authors: Elena Chiappini; Francesca Santamaria; Gian Luigi Marseglia; Paola Marchisio; Luisa Galli; Renato Cutrera; Maurizio de Martino; Sara Antonini; Paolo Becherucci; Paolo Biasci; Barbara Bortone; Sergio Bottero; Valeria Caldarelli; Fabio Cardinale; Guido Castelli Gattinara; Martina Ciarcià; Daniele Ciofi; Sofia D'Elios; Giuseppe Di Mauro; Mattia Doria; Luciana Indinnimeo; Andrea Lo Vecchio; Francesco Macrì; Roberto Mattina; Vito Leonardo Miniello; Michele Miraglia Del Giudice; Guido Morbin; Marco Antonio Motisi; Andrea Novelli; Anna Teresa Palamara; Maria Laura Panatta; Angela Pasinato; Diego Peroni; Katia Perruccio; Giorgio Piacentini; Massimo Pifferi; Lorenzo Pignataro; Emanuela Sitzia; Chiara Tersigni; Sara Torretta; Irene Trambusti; Giulia Trippella; Diletta Valentini; Sandro Valentini; Attilio Varricchio; Maria Carmen Verga; Claudio Vicini; Marco Zecca; Alberto Villani Journal: Ital J Pediatr Date: 2021-10-25 Impact factor: 2.638